

1 **Optimising social mixing strategies achieving COVID-19 herd**
2 **immunity while minimising mortality in six European countries**

3 Romain Ragonnet ^{1,*}, Guillaume Briffoteaux ^{2,3}, Bridget M. Williams ¹, Julian Savulescu ^{4,5},
4 Matthew Segal ¹, Milinda Abayawardana ¹, Rosalind M. Eggo ⁶, Daniel Tuytens ²,
5 Nouredine Melab ³, Ben J. Marais ⁷, Emma S. McBryde ⁸, James M. Trauer ¹.

6

7 ¹ School of Public Health and Preventive Medicine, Monash University, Melbourne VIC
8 3004, Australia

9 ² Mathematics and Operational Research Department, University of Mons, 7000 Mons,
10 Belgium

11 ³ CNRS CRIStAL, Inria Lille, Université de Lille, 59000 Lille, France

12 ⁴ Murdoch Children's Research Institute, Parkville VIC 3065, Australia

13 ⁵ Uehiro Centre for Practical Ethics, University of Oxford, Oxford OX1 1PT, UK

14 ⁶ Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene &
15 Tropical Medicine, London WC1E 7HT, UK

16 ⁷ Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney,
17 Westmead NSW 2145, Australia

18 ⁸ Australian Institute of Tropical Health and Medicine, James Cook University, Douglas QLD
19 4814, Australia

20

- 21 *Corresponding author: Dr Romain Ragonnet, Monash School of Public Health and
- 22 Preventive Medicine, 553 St Kilda Road Melbourne VIC 3004,
- 23 romain.ragonnet@monash.edu, +61 3 9903 0444.

24 **Abstract**

25 Strategies are needed to minimise the impact of COVID-19 in the medium-to-long term, until
26 safe and effective vaccines can be used. Using a mathematical model in a formal optimisation
27 framework, we identified contact mitigation strategies that minimised COVID-19-related
28 mortality over a time-horizon of 15 months while achieving herd immunity in six or 12
29 months, in Belgium, France, Italy, Spain, Sweden, and the UK. We show that manipulation
30 of social contacts by age can reduce the impact of COVID-19 considerably in the presence of
31 intense transmission. If immunity was persistent, the optimised scenarios would result in herd
32 immunity while causing a number of deaths considerably lower than that observed during the
33 March-April European wave in Belgium, France, Spain and Sweden, whereas the numbers of
34 deaths required to achieve herd immunity would be comparable to somewhat larger than the
35 past epidemics in Italy and the UK. Our results also suggest that countries' herd immunity
36 thresholds may be considerably lower than first estimated for SARS-CoV-2. If post-infection
37 immunity was short-lived, ongoing contact mitigation would be required to prevent major
38 epidemic resurgence.

39

40

41 **Introduction**

42 The rapid spread of SARS-CoV-2 has resulted in millions of cases of COVID-19 and
43 hundreds of thousands of deaths. This has resulted in a global crisis that has overwhelmed
44 health care systems and induced economic hardship in many settings.

45 In an effort to control the epidemic, many governments have implemented severe restrictions
46 on population movement and social mixing. These have varied in scope and stringency¹, and
47 have included ‘stay at home’ orders, travel restrictions, and school and business closures.

48 Although these measures, combined with extensive testing, quarantine, and contact tracing
49 with isolation, have been successful in reducing transmission in many countries, the adverse
50 community-wide effects of these restrictions have been severe. Evidence from the United
51 Kingdom (UK) suggests restrictions have had negative effects on mental health², and non-
52 COVID-19 health through delays in diagnostic services³.

53 In the absence of a vaccine, there are few alternative approaches to combating the pandemic;
54 each associated with major drawbacks which should be objectively quantified. Although
55 elimination of infection has been successful in some settings, attempts to ease restrictions
56 have often resulted in epidemic recurrence. As long as a large proportion of the population
57 remains susceptible to SARS-CoV-2 infection, populations will remain at high risk of
58 resurgences of transmission. Reaching a level of post-infection immunity in the population
59 that results in the effective reproduction number remaining below 1 (also called “herd
60 immunity”) can be part of a strategy to minimise population health impacts over the medium-
61 to-long term⁴.

62 As countries may not be able to sustain strict movement and contact restrictions in the
63 medium-to-long term, it is important to identify which restrictions can be lifted with lesser
64 impacts than a relaxation of measures across all ages and locations.

65 Countries such as Sweden have tried to minimise the impact of the disease with less
66 restrictive measures, to slow transmission while shielding those at greatest risk⁵. However,
67 Swedish authorities have acknowledged errors in implementation, particularly around
68 infection prevention in aged residential care facilities⁶. The UK also initially aimed for a
69 limited lockdown with shielding of at-risk groups, but changed course after modelling
70 suggested that without drastic measures, hundreds of thousands of deaths would be expected⁷.
71 Permitting SARS-CoV-2 transmission in the community is clearly associated with negative
72 consequences, including the potential long-term effects of COVID-19 that are still poorly
73 understood and the potential overwhelming of health systems. However, until safe and
74 effective vaccines can be deployed at scale, all strategies are associated with serious risks and
75 adverse effects. It is therefore necessary to evaluate the merits and risks of each approach.

76 We present an optimisation analysis that aims to identify strategies of social contact
77 restrictions resulting in non-vaccine herd immunity within six or 12 months while minimising
78 the number of COVID-19-related deaths or years of life lost (YLLs) over a time-horizon of
79 15 months in six highly-affected countries: Belgium, France, Italy, Spain, Sweden, and the
80 UK. We consider strategies that either altered age- or location-specific contact patterns.

81

82

83 **Results**

84 **Model calibration**

85

86 Model fits to local data on COVID-19 cases, hospitalisations, deaths and seroprevalence are
87 shown in Figure 1. Our model was able to replicate the observed dynamics of the different
88 disease indicators in the six countries. Our approach of allowing for time-variant case
89 detection successfully captured the differences observed between the profiles of confirmed
90 cases and those of hospitalisations or deaths. For example, in Sweden the model was able to
91 replicate the increase observed in the number of confirmed cases in June 2020 while other
92 disease indicators were declining. This is explained by a testing surge that occurred in June in
93 Sweden⁸, and that was automatically captured by our Bayesian model calibration (Figure S8).

94 The posterior parameter estimates and inferred time-variant profiles of case detection
95 obtained during the model calibration process are presented in Supplementary Section 2.4.
96 While the posterior distributions of most epidemiological parameters were broadly similar
97 across the six countries, we observed significant differences regarding the estimates of
98 mortality rates, detection profiles and the inferred effect of micro-distancing (i.e. the
99 reduction of the per-contact risk of transmission attributable to preventive measures such as
100 mask wearing or physical distancing). The modelled infection fatality rates were found to be
101 higher in the UK and Belgium compared to the other countries. This finding has also been
102 reported in previous studies and may be explained by differences in the criteria used to
103 determine whether deaths are COVID-19-related^{9,10}. We also found that higher levels of case
104 detection had to be modelled in France and Sweden compared to the other countries in order
105 to capture the different disease indicators accurately. We noted that the dynamics of the
106 Swedish epidemic were best captured when micro-distancing was applied sooner and at a

107 higher level compared to the other countries. Finally, small variations were also observed in
108 the risk of transmission per contact between countries, which can be explained by the fact
109 that the contact matrices used to inform the model only capture the average number of
110 contacts per day but fail to account for other contact characteristics such as contact duration
111 or intensity.

112 In order to validate the age-specific dynamics of the models, we compared the modelled age-
113 specific proportions of recovered individuals with estimates of seroprevalence by age
114 obtained from 24 serosurveys (Supplementary Section 5.1), covering all countries except
115 Italy for which age-specific estimates were not available. These comparisons demonstrated
116 that the model estimates were consistent with serosurvey measures, especially when surveys
117 were conducted shortly after the first epidemic waves. In contrast, the proportions of
118 recovered individuals predicted by the model tended to overestimate observed seroprevalence
119 for the surveys that were conducted at later times, which is consistent with the known decline
120 in antibody prevalence over time since infection¹⁰.

121 **Optimisation results**

122 In all countries, age-specific mixing restrictions resulted in fewer deaths and YLLs than
123 location-specific mixing reductions (Table 1), although both generated considerably fewer
124 deaths and YLLs compared to an unmitigated scenario. The optimisations also led to
125 reductions of up to 50% in the final proportion of ever-infected individuals, compared to the
126 unmitigated scenario (Table 2). The total number of deaths occurring after the start of the
127 optimised intervention on 1st October 2020 was significantly lower than the number of deaths
128 that had occurred before this time in Belgium, France, Spain and Sweden when considering
129 optimisation by age. In contrast, achieving herd immunity while optimising mixing by

130 location would lead to a greater number of deaths compared to those that had occurred before
131 the 1st October 2020 in all countries.

132 We observed broadly consistent mixing patterns across all the countries considered under the
133 optimised mitigation strategies. Namely, contacts of older adults were restricted most, while
134 contacts of individuals aged between 15 and 49 years old were maintained near pre-COVID-
135 19 levels for optimisation of deaths or YLLs (Figure 2). Contacts involving children and
136 adolescents were also maintained at or near 100% in most countries under the optimised
137 scenarios. The mortality indicators (deaths and YLLs) were highly sensitive to small
138 perturbations in the mixing contributions of young-to-middle-age adults considered in the
139 sensitivity analyses. In contrast, the contact rates involving children and adolescents could
140 deviate significantly from the optimal plan without substantially compromising outcomes.

141 Optimising for YLLs, rather than deaths, resulted in a larger decrease in contacts needed in
142 the 50-54-year-old age-group across most scenarios. These reductions were compensated by
143 contact increases in younger age groups, as these groups are associated with a lower mortality
144 risk. The patterns of optimal mixing by age were similar between the six-month and 12-
145 month mitigation strategies, although the longer scenario necessitated slightly greater contact
146 reductions.

147 While the base-case analyses assumed a minimum threshold of 10% for the mixing factors,
148 we considered alternate lower bounds in a sensitivity analysis (Supplement, Section 5.1). We
149 observed that the two mortality indicators increased roughly linearly, as the minimum mixing
150 threshold was raised (Figure S15). Considering a threshold of 20%, we predicted that the
151 number of deaths required to reach herd immunity would increase by 30 to 65% compared to
152 the base-case analyses assuming a 10% minimum threshold.

153 Figure 3 shows the optimised mixing patterns by location..

154 **Projected epidemics**

155 The trajectories of the optimised epidemics are shown in Figure 4. The younger populations
156 were considerably more affected in the optimised strategies, resulting in a much lower ratio
157 of deaths to incident disease episodes compared with the first wave. The median percentage
158 of the population ever-infected with SARS-CoV-2 at the end of the simulation on 31
159 December 2021 ranged between 30% and 52%, depending on the country and the scenario
160 considered (Table 2 and Figures S18-19). These percentages represent overestimates of herd
161 immunity thresholds, since achieving herd immunity by the end of the intervention was a
162 constraint of the optimisation algorithm. The percentages of the population ever-infected with
163 SARS-CoV-2 are also presented by age-group in Figures S20-21.

164 Our model projected that optimising social contacts by age could achieve herd immunity with
165 lower or similar hospital occupancies to those observed in March and April in Belgium and
166 France, whereas more hospital beds would be required in the other four countries (Figure 5).
167 Our results also suggest that a longer mitigation phase could reduce the peak and total
168 hospital burden, although the differences between the two durations in terms of COVID-19-
169 related mortality and final epidemic size were minor (Tables 1 and 2).

170 **Effect of waning immunity**

171 The four simulated scenarios of waning immunity considered different durations of post-
172 infection immunity, as well as different assumptions regarding the effect of previous
173 infection on disease severity for repeated infections. Using the six-month age-specific
174 mitigation scenario, we found that under the four tested scenarios of waning immunity a third
175 epidemic wave would occur by the end of 2021 in the absence of further intervention in all
176 countries (Figure 6). The duration of post-infection immunity affected the future epidemics
177 much more than the extent of protection against severe disease. Under the assumption of a

178 six-month immunity duration, the predicted peak deaths and hospitalisations during epidemic
179 resurgence were more than double those observed during the first wave or the mitigation
180 phase in all countries.

181 Finally, we simulated scenarios considering our most pessimistic assumption of waning
182 immunity but applying mild mixing restrictions after the mitigation phase (Figure 7). Our
183 results suggest that relative mixing reductions of 30% would be required to maintain the
184 epidemics at low levels until the end of 2021 in all countries except France and Sweden,
185 where a 20% reduction may suffice to prevent significant resurgence.. These mixing
186 reductions were defined as universal reductions relative to the pre-COVID-19 era.

187

188

189 **Discussion**

190 Our model suggests that altering age-specific mixing patterns can dramatically reduce the
191 mortality-related impacts of COVID-19 over the medium-to-long term. We estimate that
192 strategies based on contact mitigation by age could achieve non-vaccine herd immunity with
193 mortality that is considerably lower than has been previously observed in Belgium, France,
194 Spain and Sweden, whereas the numbers of deaths required to achieve herd immunity would
195 be comparable to somewhat larger than the first wave in Italy and the UK. We also highlight
196 the critical need for improved knowledge around post-infection immunity duration if such
197 strategies are to be considered.

198 We quantify the contact patterns that are most likely to result in decreased mortality or YLLs,
199 providing guidance on targeted release strategies. While many governments have used
200 mitigation strategies based on location-specific restrictions, such as school or business
201 closures, we demonstrate that strategies considering age-selective restrictions would have a
202 greater impact on the countries' epidemics, as the predicted number of future deaths was two-
203 to-four times lower when optimising by age compared to optimising by location. Across all
204 six countries included in our analysis, our model suggested that over 1 million deaths could
205 potentially be averted, and over 20 million life-years saved, by employing age-specific
206 mitigation compared to an unmitigated scenario. Such outcomes were obtained by imposing
207 highly stringent contact reductions on individuals aged over 50, while returning interactions
208 involving children and young-to-middle-aged adults to pre-COVID-19 levels in most
209 countries. This age cut-off is lower than considered in previous studies investigating age-
210 based shielding strategies^{11,12}.

211 The stringency of the optimal restrictions on social contacts of people aged 50 years and over
212 raises concerns about the feasibility of achieving the required age-differential mixing. For

213 example, the optimised results we present rely on the assumption that the opportunity of
214 effective contact could be reduced by up to 90%. It is to be noted that such reductions may be
215 achieved by combining both mobility and gathering restrictions with reductions in the per-
216 contact risk of transmission through preventive measures (i.e. micro-distancing, including
217 masks, improved hygiene, physical distancing), such that interpersonal contacts would not
218 need to be reduced to such an extreme degree. Nevertheless, even with micro-distancing, it
219 may be impossible to achieve such reductions in many settings, including multigenerational
220 households or residential aged care. Furthermore, we observed that the numbers of deaths and
221 YLLs were highly sensitive to perturbations in some of the mixing variables, indicating that
222 the strategies may rapidly become suboptimal if the targeted contact mitigation plan could
223 not be implemented precisely. This indicates that the optimised number of deaths and YLLs
224 should be interpreted as a representation of what could ideally be achieved under a best-case
225 scenario. Practical implementation would require further analyses and critical consideration
226 of tailored strategies to specific settings. Finally, our analyses considering less extreme
227 restrictions showed that mortality would increase significantly compared to the optimised
228 scenarios.

229 Our analyses showed that a longer duration of the optimised mitigation phase was associated
230 with slightly improved outcomes compared to the shorter scenario. We note that this finding
231 is intuitive, since the ensemble of acceptable mixing factor combinations associated with the
232 shorter scenario (i.e. all mitigation strategies leading to herd immunity in 6 months) is
233 necessarily included in that associated with the longer scenario (i.e. all mitigation strategies
234 leading to herd immunity in 12 months). More practically, this is explained by the fact that
235 more intense social mixing would be required if herd immunity had to be reached in a shorter
236 period of time, which implicitly induced higher minimal levels on the mixing factors for the
237 shorter scenario compared to the longer scenario. However, the benefits of increasing

238 mitigation duration in terms of averted COVID-19 deaths should be weighed against the risks
239 associated with extending the duration of social mixing manipulation.

240 It is notable that the final proportions of ever-infected individuals for each of the modelled
241 scenarios in the six countries were between 30 and 52% in all six countries. Academic and
242 public discussion has largely referred to a herd immunity threshold of between 60 and
243 70%^{13,14}, a proportion that can be readily estimated from the basic reproductive number under
244 the assumption of homogenous mixing. In reality, individuals differ as to how likely they are
245 to contract and transmit SARS-CoV-2. Several other modelling incorporating heterogeneity
246 have emerged and suggested lower estimates of the herd immunity threshold¹⁵⁻¹⁸. In
247 particular, young-to-middle-age individuals, who have higher contact rates compared to older
248 adults, contribute disproportionately to transmission, such that removing them from the
249 susceptible pool would be disproportionately effective. Our findings also have important
250 implications for vaccination strategies, as we estimated the age-specific proportions of
251 recovered individuals after herd immunity was reached, providing examples of age-specific
252 vaccination coverage that could result in herd immunity.

253 Our main projections were obtained assuming persistent post-infection immunity. Early
254 studies have shown that most people infected with SARS-CoV-2 generate both humoral and
255 cellular immune responses^{19,20}. Some studies have shown antibody levels waning over the
256 first three months post-infection, suggesting short-lived immunity²¹. However, other studies
257 have shown neutralising antibodies to persist at protective levels three²², and six months post-
258 infection²³, as well as SARS-CoV-2-specific memory lymphocytes with characteristics
259 suggestive of protective immunity up to three months post-infection²⁴. A large-scale
260 longitudinal seroprevalence study demonstrated robust humoral immune response, as
261 antiviral antibodies against SARS-CoV-2 did not decline within four months after
262 diagnosis²⁵. Infection has been shown to offer protection against reinfection in non-human

263 primates²⁶, and recent evidence suggests similar protection in humans²⁷. Although we
264 considered waning immunity under only a limited number of configurations, these highlight
265 the importance of immune effects and persistence to public health strategies.

266 We demonstrated that the selected countries' health systems would be overwhelmed if
267 immunity were to wane rapidly in the absence of any mitigation after the optimised phase.
268 Long-term restrictions would be required under such scenarios, although such restrictions
269 may consist of mild continuous contact mitigations following the optimised phase. For
270 example, 30% continued reduction in effective contacts would be needed after the optimised
271 phase in Belgium, Spain, Italy and the UK to maintain sufficient epidemic control until the
272 end of 2021.

273 Our analysis raises the question of whether it would be ethical to restrict the freedom of a
274 subset of the population, and to do so on the basis of age. Savulescu and Cameron argue that
275 age-selective lockdowns would not constitute unjust discrimination, as it involves treating
276 people differently due to a morally relevant difference: their susceptibility to severe
277 infection²⁸. They suggest that restrictions on personal freedoms would be most justified if
278 they bring about benefit to the group whose freedoms are restricted. It is also possible that
279 restriction of freedom of individuals could be reduced through the use of immunity passports,
280 though these raise further ethical and practical issues²⁹. Factors other than age also impact
281 COVID-19 risk³⁰. These factors are also important to consider when designing policies,
282 although we do not explicitly account for these other risk factors.

283 The results for optimising for deaths or for YLLs were slightly different. This raises the
284 question of what the optimisation target should be, and a welfare-adjusted life year, such as
285 the quality-adjusted life year, may be preferable. Our analysis did not include the morbidity
286 of illness or possible long-term sequelae of infection. Data on longer term outcomes suggest

287 that most people who experience mild to moderate infections recover within two to three
288 weeks³¹, although some experience prolonged symptoms or long-term sequelae³². These data
289 will be essential to optimise for morbidity. It must be noted that our analysis was based on
290 epidemiological indicators only and the optimisation trade-off was introduced by the
291 competition between the infections required to increase population immunity and mortality
292 that were minimised. Previous works also considered optimisation of COVID-19 control in a
293 mathematical modelling framework. Perkins and España chose to minimise a single objective
294 combining the number of deaths and the level of control by non-pharmaceutical
295 interventions³³. In another analysis, age-specific interventions were considered in an
296 optimisation exercise based on a single objective function combining COVID-19-related
297 mortality and the cost of the interventions and highlighted the benefit of age-targeted
298 control³⁴. However, the interpretation of these analyses is strongly dependent upon the
299 definition of the intervention cost, which remains to be adequately quantified. Indeed,
300 combining deaths and control cost into a single objective implies that these two components
301 can be measured in the same unit, while their respective contributions to the objective remain
302 extremely difficult to characterise.

303 Our approach has some technical limitations. We used previously published synthetic contact
304 matrices, which allowed a consistent approach across the six countries and incorporation of
305 location-specific contact rates³⁵. The model assumes that mixing patterns in countries are
306 well represented by these matrices and does not capture repeated contacts between the same
307 individuals. We chose to mitigate the age-specific contact rates by applying a single
308 multiplier to each age-group, whereas more flexibility could be introduced by allowing
309 mixing between particular pairs of age-groups. Given the important uncertainties in the
310 current epidemiological knowledge of SARS-CoV-2, we chose broad ranges of parameter
311 values to inform the most critical aspects of the model, which translated into moderate

312 uncertainty ranges for several epidemiological indicators. However, we believe our approach
313 to handling uncertainty is appropriate to the current stage of the pandemic. Finally, the
314 optimised strategies identified in this study may become suboptimal if the background
315 epidemiological conditions changed significantly. In particular, we anticipate that as the
316 epidemics progress, population immunity will naturally increase such that reduced levels of
317 transmission may be required during the optimised phase to achieve herd immunity.
318 However, the fact that we observed very similar optimal mixing patterns across the six
319 countries, whereas the level of population immunity at the start of the mitigation phase
320 ranged between 7% in Italy and 13% in Belgium, suggests stability in our findings about
321 optimal strategies.

322 The present work could be refined as further knowledge arises about SARS-CoV-2
323 epidemiology, especially around the nature and magnitude of post-infection immunity. In
324 addition, alternative optimisation frameworks to the one used in this study could be assessed
325 in an attempt to further improve population outcomes. Finally, future work could include the
326 negative effects of population restrictions more explicitly in order better to address the trade-
327 off between restriction stringency and uncontrolled viral transmission.

328 Caution is also required in interpretation of our projections. It must be noted that the
329 strategies we present would undoubtedly result in a greater number of COVID-19-specific
330 deaths compared to approaches based on universal stringent restrictions to force the
331 reproduction number below one. Accordingly, the risks and benefits of the strategies
332 presented must be carefully weighed against those associated with universal lockdowns,
333 which also have serious negative effects^{2,3}. The right balance between these approaches will
334 likely depend on how long we will have to wait until long-term solutions such as vaccines
335 can be deployed and is a societal choice that should be informed by epidemiological analysis.

336 In conclusion, we found that strategies can minimise deaths or YLLs over the medium-to-
337 long term while allowing an increase in population mixing if interpersonal contact patterns
338 can be manipulated to prevent transmission to older adults. In particular, modification of
339 contact rates by age is the key factor, although age-independent vulnerabilities also require
340 consideration. We show the cut-off for contact restriction - analogous to shielding or
341 cocooning - may occur at a younger age than previously assumed. Finally, our findings
342 suggest that strategies combining a phase of age-selective contact restrictions designed to
343 increase population immunity followed by ongoing but mild contact mitigation could
344 maintain transmission at low levels even with short-lived post-infection immunity.

345

346 **Methods**

347 **General approach**

348 We used a compartmental model to simulate SARS-CoV-2 transmission in the six countries
349 analysed. These were the six highest ranked countries in COVID-19 deaths per capita as
350 reported by the World Health Organization on 15th July 2020, excluding countries of less
351 than one million people. After calibrating the model using local data, we manipulated social
352 mixing patterns for an intervention period of six or 12 months starting from 1st October 2020.
353 During this phase, we identified the changes to contact patterns that would minimise COVID-
354 19-related mortality or YLLs over a time-horizon of 15 months (i.e. ending 31st December
355 2021), while ensuring all restrictions could be relaxed after the intervention phase without
356 resurgence. We also explored scenarios of waning immunity to project the future epidemics
357 under the identified optimal plans.

358 **Transmission model**

359 We explicitly simulated six infection states using a susceptible compartment, two pre-disease
360 compartments (including one presymptomatic infectious), two disease states (early and late
361 stages) and a recovered compartment (Supplementary Section 1.2). Infectious states were
362 stratified according to severity, as well as estimated detection and hospitalisation fractions.

363 We employed age-specific parameter values to characterise susceptibility to infection, disease
364 severity and risk of death (Table S3). We used previously published age-specific contact
365 matrices by location (home, schools, workplace, other locations) to inform heterogeneous
366 mixing by age³⁵.

367 We modelled physical distancing by reducing the location-specific contact rates in the three
368 non-household locations. We also included micro-distancing by reducing the transmission

369 probability in non-household contacts, reflecting preventive measures taken to reduce the per-
370 contact transmission probability, such as keeping a greater distance, hygiene measures, and
371 wearing masks.

372 Under the base-case assumption of persistent immunity, recovered individuals were assumed
373 to be permanently protected against future infection. Four scenarios of waning immunity
374 were also considered by assuming that recovered individuals became susceptible to
375 reinfection after an average duration of six or 24 months, with or without reduced disease
376 severity during repeat SARS-CoV-2 infections (Supplementary Sections 1.2, 1.4). The model
377 code is publicly available on Github³⁶.

378 **Model fitting and simulation phases**

379 We fitted the model to observed numbers of confirmed cases, hospitalisations and deaths over
380 time. Seroprevalence data were also included as calibration targets when available
381 (Supplement Section 2.2). Fitted parameters included those governing transmission, disease
382 severity and the time-variant profiles of case detection and micro-distancing. Our simulations
383 were divided into three successive phases (Figure 8). In Phase 1 we modelled the preceding
384 SARS-CoV-2 epidemics and included social distancing measures in place in each country
385 until 31st September 2020 (Figure S4). In Phase 2 the model was run using the same
386 epidemiological parameters and detection profile as during Phase 1, but social mixing
387 interventions were optimised for six or 12 months, before being lifted in Phase 3. We
388 assumed that mild micro-distancing was maintained during Phases 2 and 3 to capture the
389 likely long-term changes in individuals' behaviours and the preventive measures undertaken
390 in the future, as public awareness of the modes of transmission of SARS-CoV-2 increases
391 relative to the early stages of the epidemics (Supplement Sections 3.2 and 3.3).

392 **Optimising contact patterns**

393 We used two different indicators to represent the disease impact in separate optimisations: the
394 number of COVID-19-related deaths and the number of YLLs due to COVID-19-related
395 deaths. The number of YLLs was estimated using the country-specific life-expectancy values
396 by age reported by the United Nations. The two objective functions were calculated over a
397 time-horizon of 15 months covering Phases 2 and 3. Two types of mitigation strategies were
398 explored. First, we allowed contact rates to vary by age by applying age-specific mixing
399 factors to the original contact matrix (Supplementary Section 3.2). A mixing factor is defined
400 as the relative opportunity of social contact that an individual of a given age has, compared to
401 the pre-COVID-19 era. Therefore, the relative contact rate of one age category with respect to
402 another is calculated as the product of the mixing factors of the age-groups of the infectious
403 and susceptible individuals. In separate analyses, we considered reductions in social mixing
404 by location where the decision variables were scaling factors applying to the location-specific
405 contact rates.

406 All decision variables were assumed to be bounded between 0.1 and one and the optimisation
407 was also constrained to solutions in which the number of incident cases did not increase after
408 the mitigation phase. Because of this constraint, significant transmission was necessary
409 during the optimised mitigation phase in order to increase the level of population immunity,
410 introducing a trade-off between the required SARS-CoV-2 infections and the COVID-19-
411 related deaths to be minimised. As the optimisation tasks were computationally-expensive,
412 the searches were performed using a Genetic Algorithm where the newly generated candidate
413 strategies were evaluated in parallel on multiple CPUs³⁷.

414 **Sensitivity analyses**

415 In order to test the sensitivity of the objective functions to alterations of each optimised
416 variable, we calculated the marginal variable deviation from the optimum that would cause an

417 excess of 20 deaths per million people (or 1000 YLLs per million people when minimising
418 YLLs) as compared to the optimum (Supplementary Section 4.3). An additional sensitivity
419 analysis was performed considering values greater than 0.1 for the lower bound of the mixing
420 factors (Supplementary Section 5.1).

421

422

423 **Contributors**

424 RR, ESM and JMT conceived the study with input from BMW, BJM and RME. RR
425 conducted the analyses. RR, JMT, MS and MA developed the code. GB, NM and DT
426 designed the optimisations and GB led their implementation. RR, BMW and JMT wrote the
427 first draft and all authors contributed to the final draft.

428 **Declaration of interests**

429 The authors declare no competing interests.

430 **Data availability**

431 No individual data were used in this study. The sources of the country-level data used to
432 calibrate our models are indicated in the Supplement.

433 **Code availability**

434 The computer code used in this study is available in a GitHub repository:
435 <https://github.com/monash-emu/AuTuMN>

436 **Acknowledgements**

437 The optimisation experiments were performed using the Grid'5000 testbed, supported by a
438 scientific interest group hosted by Inria and including CNRS, RENATER and several
439 Universities as well as other organisations (see <https://www.grid5000.fr>).

440

441 **References**

- 442 1. Hale T, Angrist N, Kira B, Petherick A, Phillips T, Webster S. Variation in
443 government responses to COVID-19 Version 6.0. Blavatnik School of Government
444 Working Paper. 2020 May.
- 445 2. Pierce M, Hope H, Ford T, et al. Mental health before and during the COVID-19
446 pandemic: a longitudinal probability sample survey of the UK population. *The Lancet*
447 *Psychiatry*. 2020;0.
- 448 3. Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on
449 cancer deaths due to delays in diagnosis in England, UK: a national, population-based,
450 modelling study. *Lancet Oncol*. 2020;0.
- 451 4. Marais BJ, Sorrell TC. Pathways to COVID-19 ‘community protection.’ *International*
452 *Journal of Infectious Diseases*. 2020.
- 453 5. The Public Health Agency of Sweden. COVID-19: The Swedish strategy [Internet].
454 2020. Available from: [https://www.folkhalsomyndigheten.se/the-public-health-agency-](https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-control/covid-19--the-swedish-strategy/)
455 [of-sweden/communicable-disease-control/covid-19--the-swedish-strategy/](https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-control/covid-19--the-swedish-strategy/)
- 456 6. Paterlini M. “Closing borders is ridiculous”: the epidemiologist behind Sweden’s
457 controversial coronavirus strategy. *Nature*. 2020;580:574.
- 458 7. Ferguson NM, Laydon D, Nedjati-Gilani G, et al. Impact of non-pharmaceutical
459 interventions (NPIs) to reduce COVID-19 mortality and healthcare demand.
460 *ImperialAcUk*. 2020;3–20.
- 461 8. Ludvigsson JF. The first eight months of Sweden’s COVID-19 strategy and the key
462 actions and actors that were involved. *Acta Paediatr*. 2020;apa.15582.
- 463 9. Levin AT, Cochran KB, Walsh SP. Assessing the Age Specificity of Infection Fatality

- 464 Rates for COVID-19: Meta-Analysis & Public Policy Implications. medRxiv. Cold
465 Spring Harbor Laboratory Press; 2020 Jul.
- 466 10. Herzog S, Bie J De, Abrams S, et al. Seroprevalence of IgG antibodies against SARS
467 coronavirus 2 in Belgium: a prospective cross-sectional study of residual samples.
468 *medRxiv*. 2020;
- 469 11. Zandvoort K van, Jarvis CI, Pearson C, et al. Response strategies for COVID-19
470 epidemics in African settings: a mathematical modelling study. *medRxiv*. 2020;
- 471 12. Davies NG, Kucharski AJ, Eggo RM, et al. Effects of non-pharmaceutical
472 interventions on COVID-19 cases, deaths, and demand for hospital services in the UK:
473 a modelling study. *Lancet Public Heal*. 2020;5:e375–85.
- 474 13. Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Vol. 52,
475 Immunity. Cell Press; 2020. p. 737–41.
- 476 14. Popovich N, Sanger-Katz M. The World Is Still Far From Herd Immunity for
477 Coronavirus - The New York Times. The New York Times. 2020;
- 478 15. Brennan P V, Brennan LP. Susceptibility-adjusted herd immunity threshold model and
479 potential R0 distribution fitting the observed Covid-19 data in Stockholm. *medRxiv*.
480 2020;
- 481 16. Britton T, Ball F, Trapman P. A mathematical model reveals the influence of
482 population heterogeneity on herd immunity to SARS-CoV-2. *Science*. 2020;
- 483 17. Gomes MGM, Corder RM, King JG, et al. Individual variation in susceptibility or
484 exposure to SARS-CoV-2 lowers the herd immunity threshold. *medRxiv*. 2020;
- 485 18. Aguas R, Corder RM, King JG, Gonçalves G, Ferreira MU, Gabriela Gomes MM.
486 Herd immunity thresholds for SARS-CoV-2 estimated from unfolding epidemics.

- 487 *medRxiv*. 2020;
- 488 19. Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-Specific Humoral and
489 Cellular Immunity in COVID-19 Convalescent Individuals. *Immunity*. 2020;52:971-
490 977.e3.
- 491 20. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and
492 international spread of the 2019-nCoV outbreak originating in Wuhan, China: a
493 modelling study. *Lancet*. 2020;395:689–97.
- 494 21. Ibarondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid Decay of Anti–SARS-CoV-
495 2 Antibodies in Persons with Mild Covid-19. *N Engl J Med*. 2020;
- 496 22. Wajnberg A, Amanat F, Firpo A, et al. SARS-CoV-2 infection induces robust,
497 neutralizing antibody responses that are 1 stable for at least three months 2 3. *medRxiv*.
498 2020;2020.07.14.20151126.
- 499 23. Wu J, Liang B, Chen C, et al. SARS-CoV-2 infection induces sustained humoral
500 immune responses in convalescent patients following symptomatic COVID-19
501 Correspondence. *medRxiv*. 2020;2020.07.21.20159178.
- 502 24. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in
503 convalescent individuals with asymptomatic or mild COVID-19. *Cell*. 2020;
- 504 25. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to
505 SARS-CoV-2 in Iceland. *N Engl J Med*. 0:null.
- 506 26. Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against
507 rechallenge in rhesus macaques. *Science (80-)*. 2020;eabc4776.
- 508 27. Addetia A, Crawford KH, Dingens A, et al. Neutralizing antibodies correlate with
509 protection from SARS-CoV-2 in humans during a 1 fishery vessel outbreak with high

- 510 attack rate 2 3. *medRxiv*. 2020;2020.08.13.20173161.
- 511 28. Savulescu J, Cameron J. Why lockdown of the elderly is not ageist and why levelling
512 down equality is wrong. *J Med Ethics*. 2020;0:1–5.
- 513 29. Brown RCH, Savulescu J, Williams B, Wilkinson D. Passport to freedom? Immunity
514 passports for COVID-19. *J Med Ethics*. 2020;medethics-2020-106365.
- 515 30. Williamson EJ, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated with
516 COVID-19 death in 17 million patients. *Nature*. 2020;
- 517 31. Tenforde MW, Billig Rose E, Lindsell CJ, et al. Characteristics of Adult Outpatients
518 and Inpatients with COVID-19 — 11 Academic Medical Centers, United States,
519 March–May 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69:841–6.
- 520 32. Mahase E. Covid-19: What do we know about “long covid”? Vol. 370, The BMJ. BMJ
521 Publishing Group; 2020.
- 522 33. Perkins TA, España G. Optimal Control of the COVID-19 Pandemic with Non-
523 pharmaceutical Interventions. *Bull Math Biol*. 2020;82:118.
- 524 34. Richard Q, Alizon S, Choisy M, Sofonea MT, Djidjou-Demasse R. Age-structured
525 non-pharmaceutical interventions for optimal control of COVID-19 epidemic.
- 526 35. Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using
527 contact surveys and demographic data. *PLoS Comput Biol*. 2017;13:e1005697.
- 528 36. Trauer J, Ragonnet R, Segal M, Abayawardana M, McBryde E. AuTuMN Github
529 repository. 2019.
- 530 37. Talbi E-G. Metaheuristics: From Design to implementation. John Wiley & Sons, Ltd;
531 2009.

532 **Figure captions**

533 **Figure 1. Model projections compared against local data**

534 The figures present the median estimates (dark blue line) and the central 95% credible
535 intervals (light blue shade) against observed numbers of confirmed COVID-19 cases,
536 hospitalisations, deaths and seroprevalence (black dots). The x-axis represents the dates of
537 year 2020. The data points represent the weekly average of the daily counts for cases,
538 hospitalisations and deaths.

539

540 **Figure 2. Optimal mixing pattern with contact mitigation by age**

541 The red bars and the blue bars represent the optimised age-specific mixing factors when
542 minimising the number of deaths and years of life lost, respectively. The mixing factors are
543 presented as relative values compared to the pre-COVID-19 era for each age group. A value
544 of 1 means that individuals have the same opportunity of effective contact as before the
545 pandemic, whereas a value of 0.1 indicates a 90% reduction in effective contact opportunity.
546 To determine the relative effective contact rate of one age category with another, the relative
547 mixing values of each of the two categories must be multiplied together to reflect both the
548 contactor's and the contactee's reduction in contact opportunity. The coloured background
549 represents the acceptable region for the mixing factors (i.e. the interval [0.1 - 1]). The thin
550 black bars represent the maximum change in individual age-group contributions that would
551 cause an excess of no more than 20 deaths per million people (red bars) or 1000 YLLs per
552 million people (blue bars) as compared to the optimal plan, while still reaching herd
553 immunity by the end of the mitigation phase. The left and right panels show the result
554 obtained when assuming that the mitigation phase lasts 6 and 12 months, respectively. The
555 optimisations were performed based on the countries' maximum a posteriori parameter sets.

556

557 **Figure 3. Optimal mixing pattern with contact mitigation by location**

558 Red and blue bars represent the optimised relative contact rates by location when minimising
559 the number of deaths and years of life lost, respectively. The mixing variables are presented
560 as relative values compared to the pre-COVID-19 era for each location. A value of 1
561 represents unchanged location-specific contact rates compared to before the pandemic,
562 whereas a value of 0.1 indicates a 90% reduction in contact rates. The tan-coloured
563 background represents the acceptable region for the mixing factors (i.e. the interval [0.1 - 1]).
564 The thin black bars represent the maximum change in individual age-group contributions that
565 would cause an excess of no more than 20 deaths per million people (red bars) or 1000 YLLs
566 per million people (blue bars) as compared to the optimal plan, while still reaching herd
567 immunity by the end of the mitigation phase. The left panels show the result obtained when
568 assuming that the mitigation phase lasts 6 months. In the right panels, a longer duration of 12
569 months was allowed to achieve herd immunity. The optimisations were performed based on
570 the countries' maximum a posteriori parameter sets.

571

572 **Figure 4. Age-specific profile of disease incidence, COVID-19-related deaths and**
573 **proportion recovered over time optimised for life-years lost (6-month mitigation by age)**

574 The yellow background indicates the 6-month mitigation phase during which age-specific
575 contacts were optimised. These projections were produced assuming that recovered
576 individuals have persistent immunity against SARS-CoV-2 reinfection and using the
577 maximum a posteriori parameter sets.

578

579 **Figure 5. Projected hospital occupancy during the first wave compared to a mitigated**
580 **wave that would achieve herd immunity (optimised mitigation by age, persistent**
581 **immunity assumed)**

582 The modelled past epidemics are represented in purple while the projections of the mitigated
583 epidemics are represented in blue. The future epidemics are those associated with the four
584 different optimisation configurations: six- or 12-month mitigation minimising total number of
585 deaths or years of life lost (YLLs). The light shades show the central 95% credible intervals,
586 the dark shades show the central 50% credible intervals and the solid lines represent the
587 median estimates.

588

589 **Figure 6. Projected COVID-19 incidence, mortality and hospital occupancy over time**
590 **under various assumptions of waning immunity**

591 Projections were obtained using the maximum a posteriori parameter sets and based on the 6-
592 month contact mitigation by age minimising years of life lost (YLLs). The yellow
593 background indicates the mitigation phase during which age-specific contacts were
594 optimised. Five different assumptions were used to project the disease indicators: persistent
595 immunity (black), 24-month average duration of immunity with and without 50% reduction
596 in risk of symptoms for repeat infections (red and coral, respectively), 6-month average
597 duration of immunity with and without 50% reduction in risk of symptoms for repeat
598 infections (blue and turquoise, respectively).

599

600 **Figure 7. Projected COVID-19 incidence, mortality and hospital occupancy over time**
601 **with short-lived post-infection immunity and applying mild mixing reductions after the**
602 **optimised phase**

603 The predictions were obtained using the maximum a posteriori parameter sets and based on
604 the 6-month contact mitigation by age minimising years of life lost (YLLs). The yellow
605 background indicates the mitigation phase during which age-specific contacts were
606 optimised. These predictions were obtained assuming 6-month average duration of immunity
607 with no effect on the severity of repeat SARS-CoV-2 infections. The mixing factors were
608 defined in the same way as during optimisation except that the same factor was applied to all
609 age-groups. That is, a 90% mixing factor corresponds to a situation where every individual
610 reduces their opportunity of contact by 10%.

611

612 **Figure 8. Illustration of the three simulation phases**

613 Numbered circles indicate the different phases: capturing past dynamics (1), manipulating
614 social mixing to achieve herd immunity with minimum COVID-19 impacts (2, highlighted
615 with yellow background), testing for epidemic resurgence (3). Panel a. shows an example
616 simulation where herd immunity was reached by the end of Phase 2, whereas Panel b. shows
617 a configuration that failed to achieve herd immunity.

618

619 **Tables**

620

621

Country	Optimisation mode	Mitigation phase	Deaths before 1 Oct 2020 (thousands)		Deaths from 1 Oct 2020 (thousands)			YLLs before 1 Oct 2020 (thousands)	YLLs from 1 Oct 2020 (thousands)		
			Model prediction	WHO report	Unmitigated	Optimised		Model prediction	Unmitigated	Optimised	
						Minimising deaths	Minimising YLLs			Minimising deaths	Minimising YLLs
Belgium	by age	6 mo.	8.7 (6.0-12.6)	10.2	50.0 (33.9-54.0)	4.8 (3.6-5.6)	4.9 (3.7-5.6)	317 (209-466)	1497 (1085-1573)	211 (159-246)	208 (156-244)
		12 mo.				4.3 (2.4-5.1)	4.4 (2.4-5.1)			194 (110-230)	189 (108-226)
	by location	6 mo.				12.1 (9.7-16.2)	12.8 (10.3-17.2)			603 (469-699)	589 (457-683)
		12 mo.				11.0 (5.5-12.5)	11.5 (5.8-13.1)			562 (296-644)	553 (292-633)
France	by age	6 mo.	38.1 (24.3-52.7)	31.7	331.5 (245.2-412.6)	28.0 (21.3-37.9)	28.1 (21.4-38.0)	781 (452-1184)	6911 (4872-8850)	887 (594-1232)	876 (588-1219)
		12 mo.				26.5 (18.8-36.9)	26.8 (19.1-37.4)			852 (549-1234)	832 (537-1204)
	by location	6 mo.				85.8 (68.8-117.7)	86.1 (69.5-117.8)			2753 (1919-3848)	2751 (1925-3827)
		12 mo.				79.2 (56.8-115.3)	79.5 (57.1-115.7)			2547 (1710-3757)	2541 (1704-3748)
Italy	by age	6 mo.	37.2 (27.7-54.4)	35.9	391.9 (323.5-451.9)	45.0 (31.7-64.6)	55.2 (38.5-73.5)	688 (438-1165)	7331 (4789-8856)	1779 (1034-2537)	1446 (851-2020)
		12 mo.				36.1 (25.1-45.6)	36.2 (26.1-45.4)			1586 (910-2147)	1059 (623-1416)
	by location	6 mo.				199.7 (163.9-295.1)	199.6 (163.8-295.4)			4171 (2811-6386)	4172 (2810-6392)
		12 mo.				185.9 (134.6-234.0)	191.8 (138.7-241.2)			3965 (2538-5019)	3903 (2495-4952)
Spain	by age	6 mo.	33.3 (15.2-48.0)	32.4	232.4 (164.0-332.1)	22.5 (16.7-35.6)	22.5 (16.7-35.8)	462 (212-873)	3468 (2388-7132)	602 (433-1374)	501 (362-1104)
		12 mo.				20.7 (15.4-32.9)	21.1 (15.6-33.0)			510 (368-1138)	469 (340-1023)
	by location	6 mo.				68.4 (50.3-100.3)	68.9 (50.6-101.2)			1420 (1011-3131)	1415 (1008-3123)
		12 mo.				66.4 (49.3-95.0)	66.6 (49.4-95.1)			1384 (998-3030)	1380 (997-3019)
Sweden	by age	6 mo.	5.8 (4.9-6.7)	5.9	31.4 (23.7-37.3)	3.1 (2.1-4.0)	3.1 (2.1-3.9)	97 (78-116)	563 (403-696)	109 (69-143)	89 (57-117)
		12 mo.				2.9 (1.9-3.7)	2.9 (2.0-3.9)			112 (70-149)	84 (53-111)
	by location	6 mo.				10.8 (8.8-12.7)	11.1 (9.3-13.0)			281 (207-353)	277 (212-346)
		12 mo.				10.5 (7.4-12.6)	10.5 (7.4-12.7)			272 (180-345)	269 (177-342)
United Kingdom	by age	6 mo.	43.2 (30.5-56.5)	42.1	469.9 (408.3-533.4)	47.8 (40.6-57.5)	52.4 (44.7-62.8)	1307 (901-1777)	11418 (10650-12342)	1854 (1614-2199)	1758 (1515-2094)
		12 mo.				46.5 (38.3-57.0)	48.6 (40.0-59.3)			1728 (1447-2084)	1710 (1429-2069)
	by location	6 mo.				91.0 (83.2-114.0)	91.3 (83.4-114.2)			4337 (4032-5220)	4331 (4022-5205)
		12 mo.				84.8 (71.6-110.4)	86.1 (72.7-112.4)			4210 (3644-5218)	4183 (3617-5202)

622

623 **Table 1. Predicted numbers of deaths and years of life lost**

624 Optimisation realised under the assumption of persistent immunity. Numbers are presented in thousands of deaths and
 625 thousands of YLLs as median and central 95% credible intervals. YLLs: Years of life lost.

626

627

628

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Country	Optimisation mode	Mitigation phase	Proportion recovered on 1 Oct 2020 (%)	Final proportion recovered (%)		
				Unmitigated	Optimised Minimising deaths	Optimised Minimising YLLs
Belgium	by age	6 months	13 (9-20)	64 (58-68)	36 (32-40)	36 (31-40)
		12 months			35 (29-39)	34 (29-39)
	by location	6 months			38 (35-44)	39 (35-44)
		12 months			36 (29-42)	37 (29-42)
France	by age	6 months	7 (5-11)	65 (62-71)	31 (28-35)	32 (29-36)
		12 months			30 (27-35)	30 (27-34)
	by location	6 months			37 (35-43)	37 (35-43)
		12 months			35 (31-43)	35 (31-42)
Italy	by age	6 months	7 (5-10)	73 (68-78)	43 (40-47)	42 (39-46)
		12 months			39 (36-43)	39 (36-43)
	by location	6 months			50 (47-60)	50 (47-60)
		12 months			46 (39-53)	46 (39-53)
Spain	by age	6 months	9 (5-13)	79 (76-82)	41 (37-45)	41 (37-45)
		12 months			39 (34-42)	39 (35-43)
	by location	6 months			46 (42-51)	46 (42-52)
		12 months			46 (40-51)	46 (39-51)
Sweden	by age	6 months	11 (9-14)	82 (79-83)	46 (44-47)	46 (44-47)
		12 months			43 (41-44)	45 (43-46)
	by location	6 months			52 (51-54)	52 (51-55)
		12 months			51 (47-53)	51 (47-53)
UK	by age	6 months	9 (6-12)	75 (72-80)	41 (37-46)	41 (37-45)
		12 months			40 (35-44)	39 (35-44)
	by location	6 months			43 (40-50)	43 (40-50)
		12 months			42 (37-49)	42 (37-49)

629 **Table 2. Proportions of recovered individuals at the start of the mitigation phase and at the end of the**
 630 **simulation.**

631 Optimisations realised under the assumption of persistent immunity. Numbers are presented as median and central
 632 95% credible intervals. Herd immunity was reached by the end of the mitigation phase. YLLs: Years of life lost.

633

634

The next page contains Figure 1.

Figure 1. Model projections compared against local data

The figures present the median estimates (dark blue line) and the central 95% credible intervals (light blue shade) against observed numbers of confirmed COVID-19 cases, hospitalisations, deaths and seroprevalence (black dots). The x-axis represents the dates of year 2020. The data points represent the weekly average of the daily counts for cases, hospitalisations and deaths.





Italy

notifications per day

hospital occupancy

deaths per day

percentage ever infected







United Kingdom

notifications per day

new hospitalisations per day

deaths per day

percentage ever infected







France

notifications per day

new hospitalisations per day

deaths per day

percentage ever infected







Belgium

notifications per day

new hospitalisations per day

deaths per day

percentage ever infected







Spain

notifications per day

new hospitalisations per day

deaths per day

percentage ever infected







Sweden

notifications per day

new ICU admissions per day

deaths per day

percentage ever infected



medRxiv preprint doi: <https://doi.org/10.1101/2020.08.25.20182162>; this version posted November 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

The next page contains Figure 2.

Figure 2. Optimal mixing pattern with contact mitigation by age

The red bars and the blue bars represent the optimised age-specific mixing factors when minimising the number of deaths and years of life lost, respectively. The mixing factors are presented as relative values compared to the pre-COVID-19 era for each age group. A value of 1 means that individuals have the same opportunity of effective contact as before the pandemic, whereas a value of 0.1 indicates a 90% reduction in effective contact opportunity. To determine the relative effective contact rate of one age category with another, the relative mixing values of each of the two categories must be multiplied together to reflect both the contactor's and the contactee's reduction in contact opportunity. The coloured background represents the acceptable region for the mixing factors (i.e. the interval [0.1 - 1]). The thin black bars represent the maximum change in individual age-group contributions that would cause an excess of no more than 20 deaths per million people (red bars) or 1000 YLLs per million people (blue bars) as compared to the optimal plan, while still reaching herd immunity by the end of the mitigation phase. The left and right panels show the result obtained when assuming that the mitigation phase lasts 6 and 12 months, respectively. The optimisations were performed based on the countries' maximum a posteriori parameter sets.



medRxiv preprint doi: <https://doi.org/10.1101/2020.08.25.20182162>; this version posted November 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



Six-month mitigation phase

Twelve-month mitigation phase



Belgium





France





Italy





Spain



Sweden



United Kingdom



medRxiv preprint doi: <https://doi.org/10.1101/2020.08.25.20182163>; this version posted November 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

The next page contains Figure 3.

Figure 3. Optimal mixing pattern with contact mitigation by location

Red and blue bars represent the optimised relative contact rates by location when minimising the number of deaths and years of life lost, respectively. The mixing variables are presented as relative values compared to the pre-COVID-19 era for each location. A value of 1 represents unchanged location-specific contact rates compared to before the pandemic, whereas a value of 0.1 indicates a 90% reduction in contact rates. The tan-coloured background represents the acceptable region for the mixing factors (i.e. the interval [0.1 - 1]). The thin black bars represent the maximum change in individual age-group contributions that would cause an excess of no more than 20 deaths per million people (red bars) or 1000 YLLs per million people (blue bars) as compared to the optimal plan, while still reaching herd immunity by the end of the mitigation phase. The left panels show the result obtained when assuming that the mitigation phase lasts 6 months. In the right panels, a longer duration of 12 months was allowed to achieve herd immunity. The optimisations were performed based on the countries' maximum a posteriori

medRxiv preprint doi: <https://doi.org/10.1101/2020.08.25.20182162>; this version posted November 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.



It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

parameter sets.



Six-month mitigation phase

Twelve-month mitigation phase



Belgium





France





Italy





Spain



Sweden



United Kingdom



medRxiv preprint doi: <https://doi.org/10.1101/2020.08.25.20182162>; this version posted November 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

The next page contains Figure 4.

Figure 4. Age-specific profile of disease incidence, COVID-19-related deaths and proportion recovered over time optimised for life-years lost (6-month mitigation by age)




The yellow background indicates the 6-month mitigation phase during which age-specific contacts were optimised. These projections were produced assuming that recovered individuals have persistent immunity against SARS-CoV-2 reinfection and using the maximum a posteriori parameter sets.

Daily disease incidence




Daily deaths

Percentage recovered

Belgium






France






Italy




medRxiv preprint doi: <https://doi.org/10.1101/2020.08.25.20182162>; this version posted November 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).






Spain



Sweden



United Kingdom



Age:

- 75+
- 70-74
- 65-69
- 60-64
- 55-59
- 50-54
- 45-49
- 40-44
- 35-39
- 30-34
- 25-29
- 20-24
- 15-19
- 10-14
- 5-9
- 0-4

The next page contains Figure 5.

Figure 5. Projected hospital occupancy during the first wave compared to a mitigated wave that would achieve herd immunity (optimised mitigation by age, persistent immunity assumed)


The modelled past epidemics are represented in purple while the projections of the mitigated epidemics are represented in blue. The future epidemics are those associated with the four different optimisation configurations: six- or 12-month mitigation minimising total number of deaths or years of life lost (YLLs). The light shades show the central 95% credible intervals, the dark shades show the central 50% credible intervals and the solid lines represent the median estimates.

Past epidemic


6-month mitigation
minimising deaths minimising YLLs

12-month mitigation
minimising deaths minimising YLLs

Belgium




France




Italy


medRxiv preprint doi: <https://doi.org/10.1101/2020.08.25.20182162>; this version posted November 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Spain



Sweden



United Kingdom



The next page contains Figure 6.

Figure 6. Projected COVID-19 incidence, mortality and hospital occupancy over time under various assumptions of waning immunity

Projections were obtained using the maximum a posteriori parameter sets and based on the 6-month contact mitigation by age minimising years of life lost (YLLs). The yellow background indicates the mitigation phase during which age-specific contacts were optimised. Five different assumptions were used to project the disease indicators: persistent immunity (black), 24-month average duration of immunity with and without 50% reduction in risk of symptoms for repeat infections (red and coral, respectively), 6-month average duration of immunity with and without 50% reduction in risk of symptoms for repeat infections (blue and turquoise, respectively).

The next page contains Figure 7.

Figure 7. Projected COVID-19 incidence, mortality and hospital occupancy over time with short-lived post-infection immunity and applying mild mixing reductions after the optimised phase

The predictions were obtained using the maximum a posteriori parameter sets and based on the 6-month contact mitigation by age minimising years of life lost (YLLs). The yellow background indicates the mitigation phase during which age-specific contacts were optimised. These predictions were obtained assuming 6-month average duration of immunity with no effect on the severity of repeat SARS-CoV-2 infections. The mixing factors were defined in the same way as during optimisation except that the same factor was applied to all age-groups. That is, a 90% mixing factor corresponds to a situation where every individual reduces their opportunity of contact by 10%.

The next page contains Figure 8.

Figure 8. Illustration of the three simulation phases

Numbered circles indicate the different phases: capturing past dynamics (1), manipulating social mixing to achieve herd immunity with minimum COVID-19 impacts (2, highlighted with yellow background), testing for epidemic resurgence (3). Panel a. shows an example simulation where herd immunity was reached by the end of Phase 2, whereas Panel b. shows a configuration that failed to achieve herd immunity.

